Michaël Chopin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michaël Chopin has a total of 340 co-authors. Here are the top co-authors by number of shared publications:
- Stephen Laurence Nutt
Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
25 shared publications - Gabrielle T. Belz
The University of Queensland Frazer Institute, University of Queensland, Woolloongabba, Australia
10 shared publications - Yifan Zhan
Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd
8 shared publications - Nicholas D. Huntington
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
7 shared publications - Lisa Anna Mielke
Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Heidelberg, Australia
6 shared publications Andrew M. Lew
Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
5 shared publications
Latest Publications
- 8 September 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (10) , 1980-1982
ID2 orchestrates the final ‘E-scape’ from the −165-kb Zeb2 enhancer for cDC1 specification
- 8 September 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (10) , 1980-1982
ID2 orchestrates the final ‘E-scape’ from the −165-kb Zeb2 enhancer for cDC1 specification
- 3 July 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (8) , 1737-1748
Pregnancy-induced tissue-resident memory-like T cells contribute to tumor control in breast cancer
Women who have full-term pregnancies have a reduced risk of breast cancer, although the underlying mechanisms are not well understood. Here we show that tissue-resident memory-like T (TRM-like) cells are enriched in the breasts of parous women and mice compared to nulliparous individuals. These cells develop during mid-gestation, persist after lactation and are closely associated with mammary epithelial cells, suggesting dependence on epithelial-derived signals. Impaired alveolar differentiation or a deficiency in epithelial cell-derived cytokines interleukin (IL)-15 and transforming growth factor (TGF)β diminished the expansion of mammary TRM-like cells. Single-cell transcriptomics revealed the expanded TRM-like cells were heterogeneous, comprising CD8αβ+ and CD8αα+ subsets. Lineage tracing showed that these TRM-like cells acquire effector functions and contribute to tumor control. Depletion of TRM-like cells abrogated breast tumor protection in parous mice, while enhanced IL-2Rβ signaling-induced TRM-like cells and conferred protection in nulliparous mice. Together, we show a mechanism by which pregnancy can induce anticipatory breast cancer protection in a tissue-specific manner.
- 3 July 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (8) , 1737-1748
Pregnancy-induced tissue-resident memory-like T cells contribute to tumor control in breast cancer
Women who have full-term pregnancies have a reduced risk of breast cancer, although the underlying mechanisms are not well understood. Here we show that tissue-resident memory-like T (TRM-like) cells are enriched in the breasts of parous women and mice compared to nulliparous individuals. These cells develop during mid-gestation, persist after lactation and are closely associated with mammary epithelial cells, suggesting dependence on epithelial-derived signals. Impaired alveolar differentiation or a deficiency in epithelial cell-derived cytokines interleukin (IL)-15 and transforming growth factor (TGF)β diminished the expansion of mammary TRM-like cells. Single-cell transcriptomics revealed the expanded TRM-like cells were heterogeneous, comprising CD8αβ+ and CD8αα+ subsets. Lineage tracing showed that these TRM-like cells acquire effector functions and contribute to tumor control. Depletion of TRM-like cells abrogated breast tumor protection in parous mice, while enhanced IL-2Rβ signaling-induced TRM-like cells and conferred protection in nulliparous mice. Together, we show a mechanism by which pregnancy can induce anticipatory breast cancer protection in a tissue-specific manner.
- Open Access
- 24 December 2025
- Published by Elsevier in Cell Reports
- Vol. 45 (1) , 116772
Interleukin 4 selectively expands functional type 1 conventional dendritic cells from bone marrow progenitors
- 24 December 2025
- Published by Elsevier in Cell Reports
- Vol. 45 (1) , 116772
Open AccessInterleukin 4 selectively expands functional type 1 conventional dendritic cells from bone marrow progenitors
- Open Access
- 29 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1544483
Transcriptional regulatory logic orchestrating lymphoid and myeloid cell fate decisions
Introduction: The differentiation of hematopoietic stem cells (HSCs) into diverse blood and immune cells is a complex, highly hierarchical process characterized by a series of tightly regulated steps. It involves a sequence of intermediate oligo-potent progenitors making successive binary decisions. This process gradually narrows down lineage possibilities until a final fate is reached. This step-wise process is tightly controlled by transcription factors (TFs) and their associated regulome, ultimately resulting in the differentiation of both lymphoid and myeloid compartments.Methods: We unravel the lineage-specific gene regulatory circuitry controlling the development of B cells, T cells, innate lymphoid cells (ILCs), and dendritic cells (DCs). We employ weighted gene co-expression network analysis to characterize gene modules associated with the lymphoid or myeloid cell fate, enabling the identification of lineage-restricted TFs based on their expression patterns.Results: By identifying TFs whose expression is subset-restricted or those with a broader expression in the hematopoietic compartment, we construct a regulatory logic that potentially controls the development of these key immune cells. Our results point to conserved regulatory elements between ILCs, natural killer cells, and DCs. This analysis unravels an intricate relationship between each cell type and how the expression of key TFs dictates lineage specificity. We particularly dissect the elements associated with conventional DCs and plasmacytoid DCs.Discussion: In conclusion, our findings shed new light on regulatory mechanisms controlling blood cell development and offer a blueprint that can be leveraged to better understand the molecular mechanisms underpinning blood cell development.
- 29 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1544483
Open AccessTranscriptional regulatory logic orchestrating lymphoid and myeloid cell fate decisions
Introduction: The differentiation of hematopoietic stem cells (HSCs) into diverse blood and immune cells is a complex, highly hierarchical process characterized by a series of tightly regulated steps. It involves a sequence of intermediate oligo-potent progenitors making successive binary decisions. This process gradually narrows down lineage possibilities until a final fate is reached. This step-wise process is tightly controlled by transcription factors (TFs) and their associated regulome, ultimately resulting in the differentiation of both lymphoid and myeloid compartments.Methods: We unravel the lineage-specific gene regulatory circuitry controlling the development of B cells, T cells, innate lymphoid cells (ILCs), and dendritic cells (DCs). We employ weighted gene co-expression network analysis to characterize gene modules associated with the lymphoid or myeloid cell fate, enabling the identification of lineage-restricted TFs based on their expression patterns.Results: By identifying TFs whose expression is subset-restricted or those with a broader expression in the hematopoietic compartment, we construct a regulatory logic that potentially controls the development of these key immune cells. Our results point to conserved regulatory elements between ILCs, natural killer cells, and DCs. This analysis unravels an intricate relationship between each cell type and how the expression of key TFs dictates lineage specificity. We particularly dissect the elements associated with conventional DCs and plasmacytoid DCs.Discussion: In conclusion, our findings shed new light on regulatory mechanisms controlling blood cell development and offer a blueprint that can be leveraged to better understand the molecular mechanisms underpinning blood cell development.
- Open Access
- 23 May 2025
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 22 (7) , 699-711
Adjusting the scope of natural killer cells in cancer therapy
Natural killer (NK) cells have evolved to detect abnormalities in tissues arising from infection with pathogens, genomic damage, or transformation and respond rapidly to the production of potent proinflammatory and cytolytic mediators. While this acute proinflammatory response is highly efficient at orchestrating sterilizing immunity to pathogens in a matter of days, cellular transformation often avoids the innate detection mechanisms of NK cells. When cellular transformation results in malignancy, tumor cells and/or the tumor microenvironment can evolve additional mechanisms to circumvent NK cell responses, and cancer is now a dominant disease burden worldwide. Here, we review recent advances in our understanding of the combined relationship between malignancies and natural killer (NK) cells, learn from recent clinical efforts in therapeutically targeting natural killer (NK) cells in cancer and outline some emerging therapeutic concepts that aim to improve the innate immune response against cancer.
- 23 May 2025
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 22 (7) , 699-711
Open AccessAdjusting the scope of natural killer cells in cancer therapy
Natural killer (NK) cells have evolved to detect abnormalities in tissues arising from infection with pathogens, genomic damage, or transformation and respond rapidly to the production of potent proinflammatory and cytolytic mediators. While this acute proinflammatory response is highly efficient at orchestrating sterilizing immunity to pathogens in a matter of days, cellular transformation often avoids the innate detection mechanisms of NK cells. When cellular transformation results in malignancy, tumor cells and/or the tumor microenvironment can evolve additional mechanisms to circumvent NK cell responses, and cancer is now a dominant disease burden worldwide. Here, we review recent advances in our understanding of the combined relationship between malignancies and natural killer (NK) cells, learn from recent clinical efforts in therapeutically targeting natural killer (NK) cells in cancer and outline some emerging therapeutic concepts that aim to improve the innate immune response against cancer.
- Open Access
Transcriptional Regulatory Logic Orchestrating Lymphoid and Myeloid Cell Fate Decisions
The differentiation of hematopoietic stem cells (HSCs) into diverse blood and immune cells is a complex, highly hierarchical process characterized by a series of tightly regulated steps. It involves a sequence of intermediate oligo-potent progenitors making successive binary decisions. This process gradually narrows down lineage possibilities until a final fate is reached. This step-wise process is tightly controlled by Transcription Factors (TFs) and their associated regulome ultimately resulting the differentiation of both lymphoid and myeloid compartments. Here, we set to unravel the lineage-specific gene regulatory circuitry controlling the development of B cells, T cells, Innate Lymphoid Cells (ILCs), and Dendritic Cells (DCs). We employ Weighted Gene Co-expression Network Analysis (WGCNA) to characterize gene modules associated to the lymphoid or myeloid cell fate, enabling the identification of lineage restricted TFs based on their expression patterns. By identifying TFs whose expression is subset-restricted or those with a broader expression in the hematopoietic compartment we construct a regulatory logic that potentially controls the development of these key immune cells. Our results point to conserved regulatory elements between ILCs, Natural Killer cells, and DCs. This analysis unravels an intricate relationship between each cell types and how the expression of key TFs dictate lineage specificity. We particularly dissect the elements associated to conventional DCs and plasmacytoid DCs. In conclusion, our findings shed new lights on regulatory mechanisms controlling blood cell development and offer a blueprint that can be leveraged to better understand the molecular mechanisms underpinning blood cell development.
Open AccessTranscriptional Regulatory Logic Orchestrating Lymphoid and Myeloid Cell Fate Decisions
The differentiation of hematopoietic stem cells (HSCs) into diverse blood and immune cells is a complex, highly hierarchical process characterized by a series of tightly regulated steps. It involves a sequence of intermediate oligo-potent progenitors making successive binary decisions. This process gradually narrows down lineage possibilities until a final fate is reached. This step-wise process is tightly controlled by Transcription Factors (TFs) and their associated regulome ultimately resulting the differentiation of both lymphoid and myeloid compartments. Here, we set to unravel the lineage-specific gene regulatory circuitry controlling the development of B cells, T cells, Innate Lymphoid Cells (ILCs), and Dendritic Cells (DCs). We employ Weighted Gene Co-expression Network Analysis (WGCNA) to characterize gene modules associated to the lymphoid or myeloid cell fate, enabling the identification of lineage restricted TFs based on their expression patterns. By identifying TFs whose expression is subset-restricted or those with a broader expression in the hematopoietic compartment we construct a regulatory logic that potentially controls the development of these key immune cells. Our results point to conserved regulatory elements between ILCs, Natural Killer cells, and DCs. This analysis unravels an intricate relationship between each cell types and how the expression of key TFs dictate lineage specificity. We particularly dissect the elements associated to conventional DCs and plasmacytoid DCs. In conclusion, our findings shed new lights on regulatory mechanisms controlling blood cell development and offer a blueprint that can be leveraged to better understand the molecular mechanisms underpinning blood cell development.
- Open Access
BATF controls IFN I production via DC-SCRIPT in plasmacytoid dendritic cells
The basic leucine zipper ATF-like transcription factor (BATF) plays a pivotal role in coordinating various aspects of lymphoid cell biology, yet essential functions in plasmacytoid dendritic cells (pDCs) have not been reported. Here, we demonstrate that BATF deficiency leads to increased interferon (IFN) I production in Toll-like receptor 9 (TLR9)-activated pDCs, while BATF overexpression has an inhibitory effect. BATF-deficient mice exhibit elevated IFN-I serum levels early in lymphocytic choriomeningitis virus (LCMV) infection. Integrated transcriptomics and ChIP-seq approaches identified the transcriptional regulator DC-SCRIPT as a direct target of BATF that suppresses IFN-I promoter activity by interacting with interferon regulatory factor 7 (IRF7). Genome-wide association study (GWAS) analyses further implicate BATF in pDC-mediated human diseases. Our findings establish a novel negative feedback axis in IFN-I regulation in pDCs during antiviral immune responses orchestrated by BATF and DC-SCRIPT, with broader implications for pDC- and IFN-I-mediated autoimmunity.
Open AccessBATF controls IFN I production via DC-SCRIPT in plasmacytoid dendritic cells
The basic leucine zipper ATF-like transcription factor (BATF) plays a pivotal role in coordinating various aspects of lymphoid cell biology, yet essential functions in plasmacytoid dendritic cells (pDCs) have not been reported. Here, we demonstrate that BATF deficiency leads to increased interferon (IFN) I production in Toll-like receptor 9 (TLR9)-activated pDCs, while BATF overexpression has an inhibitory effect. BATF-deficient mice exhibit elevated IFN-I serum levels early in lymphocytic choriomeningitis virus (LCMV) infection. Integrated transcriptomics and ChIP-seq approaches identified the transcriptional regulator DC-SCRIPT as a direct target of BATF that suppresses IFN-I promoter activity by interacting with interferon regulatory factor 7 (IRF7). Genome-wide association study (GWAS) analyses further implicate BATF in pDC-mediated human diseases. Our findings establish a novel negative feedback axis in IFN-I regulation in pDCs during antiviral immune responses orchestrated by BATF and DC-SCRIPT, with broader implications for pDC- and IFN-I-mediated autoimmunity.
- 24 May 2023
- Published by Elsevier in Current Opinion in Immunology
- Vol. 82, 102341
Harnessing dendritic cell diversity in cancer immunotherapy
- 24 May 2023
- Published by Elsevier in Current Opinion in Immunology
- Vol. 82, 102341
Harnessing dendritic cell diversity in cancer immunotherapy
- 5 December 2022
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 20 (1) , 65-79
CIS controls the functional polarization of GM-CSF-derived macrophages
The cytokine granulocyte-macrophage-colony stimulating factor (GM-CSF) possesses the capacity to differentiate monocytes into macrophages (MØs) with opposing functions, namely, proinflammatory M1-like MØs and immunosuppressive M2-like MØs. Despite the importance of these opposing biological outcomes, the intrinsic mechanism that regulates the functional polarization of MØs under GM-CSF signaling remains elusive. Here, we showed that GM-CSF-induced MØ polarization resulted in the expression of cytokine-inducible SH2-containing protein (CIS) and that CIS deficiency skewed the differentiation of monocytes toward immunosuppressive M2-like MØs. CIS deficiency resulted in hyperactivation of the JAK-STAT5 signaling pathway, consequently promoting downregulation of the transcription factor Interferon Regulatory Factor 8 (IRF8). Loss- and gain-of-function approaches highlighted IRF8 as a critical regulator of the M1-like polarization program. In vivo, CIS deficiency induced the differentiation of M2-like macrophages, which promoted strong Th2 immune responses characterized by the development of severe experimental asthma. Collectively, our results reveal a CIS-modulated mechanism that clarifies the opposing actions of GM-CSF in MØ differentiation and uncovers the role of GM-CSF in controlling allergic inflammation.
- 5 December 2022
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 20 (1) , 65-79
CIS controls the functional polarization of GM-CSF-derived macrophages
The cytokine granulocyte-macrophage-colony stimulating factor (GM-CSF) possesses the capacity to differentiate monocytes into macrophages (MØs) with opposing functions, namely, proinflammatory M1-like MØs and immunosuppressive M2-like MØs. Despite the importance of these opposing biological outcomes, the intrinsic mechanism that regulates the functional polarization of MØs under GM-CSF signaling remains elusive. Here, we showed that GM-CSF-induced MØ polarization resulted in the expression of cytokine-inducible SH2-containing protein (CIS) and that CIS deficiency skewed the differentiation of monocytes toward immunosuppressive M2-like MØs. CIS deficiency resulted in hyperactivation of the JAK-STAT5 signaling pathway, consequently promoting downregulation of the transcription factor Interferon Regulatory Factor 8 (IRF8). Loss- and gain-of-function approaches highlighted IRF8 as a critical regulator of the M1-like polarization program. In vivo, CIS deficiency induced the differentiation of M2-like macrophages, which promoted strong Th2 immune responses characterized by the development of severe experimental asthma. Collectively, our results reveal a CIS-modulated mechanism that clarifies the opposing actions of GM-CSF in MØ differentiation and uncovers the role of GM-CSF in controlling allergic inflammation.
- Open Access
- 24 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (25) , eabl7882
Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy
Although immunotherapy has revolutionized cancer treatment, many immunogenic tumors remain refractory to treatment. This can be largely attributed to an immunologically “cold” tumor microenvironment characterized by an accumulation of immunosuppressive myeloid cells and exclusion of activated T cells. Here, we demonstrate that genetic ablation or therapeutic inhibition of the myeloid-specific hematopoietic cell kinase (HCK) enables activity of antagonistic anti–programmed cell death protein 1 (anti-PD1), anti-CTLA4, or agonistic anti-CD40 immunotherapies in otherwise refractory tumors and augments response in treatment-susceptible tumors. Mechanistically, HCK ablation reprograms tumor-associated macrophages and dendritic cells toward an inflammatory endotype and enhances CD8 + T cell recruitment and activation when combined with immunotherapy in mice. Meanwhile, therapeutic inhibition of HCK in humanized mice engrafted with patient-derived xenografts counteracts tumor immunosuppression, improves T cell recruitment, and impairs tumor growth. Collectively, our results suggest that therapeutic targeting of HCK activity enhances response to immunotherapy by simultaneously stimulating immune cell activation and inhibiting the immunosuppressive tumor microenvironment.
- 24 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (25) , eabl7882
Open AccessTherapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy
Although immunotherapy has revolutionized cancer treatment, many immunogenic tumors remain refractory to treatment. This can be largely attributed to an immunologically “cold” tumor microenvironment characterized by an accumulation of immunosuppressive myeloid cells and exclusion of activated T cells. Here, we demonstrate that genetic ablation or therapeutic inhibition of the myeloid-specific hematopoietic cell kinase (HCK) enables activity of antagonistic anti–programmed cell death protein 1 (anti-PD1), anti-CTLA4, or agonistic anti-CD40 immunotherapies in otherwise refractory tumors and augments response in treatment-susceptible tumors. Mechanistically, HCK ablation reprograms tumor-associated macrophages and dendritic cells toward an inflammatory endotype and enhances CD8 + T cell recruitment and activation when combined with immunotherapy in mice. Meanwhile, therapeutic inhibition of HCK in humanized mice engrafted with patient-derived xenografts counteracts tumor immunosuppression, improves T cell recruitment, and impairs tumor growth. Collectively, our results suggest that therapeutic targeting of HCK activity enhances response to immunotherapy by simultaneously stimulating immune cell activation and inhibiting the immunosuppressive tumor microenvironment.